drugset
drugset / Trial / NCT03728504

Study to Evaluate ASN002 in Subjects With Moderate To Severe Chronic Hand Eczema

NCT03728504 ↗

Phase 2 Completed 97 enrolled Asana BioSciences
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Randomized double-blind/placebo study to evaluate the efficacy of ASN002 in subjects with severe chronic hand eczema.

Timeline

Start
2019-01-03
Primary completion
2020-04-29
Completion
2020-04-29

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Gusacitinib Small molecule 40 mg —
Subject Gusacitinib Small molecule 80 mg —

Indications

hand dermatosis